Core Insights - The Xinjiang Listed Companies Association organized a learning exchange activity in Shanghai for 27 listed companies and related institutions, focusing on "benchmarking advanced practices and empowering enhancement" [1][2] - The event included training on regulatory policies from the Shanghai Stock Exchange, emphasizing compliance in daily operations, information disclosure, and capital operations [1] - Participants visited four benchmark companies in Shanghai to learn about their advanced experiences in technology innovation, industry operations, corporate governance, and ESG practices [2] Group 1 - The activity aimed to build an efficient learning and cooperation bridge for Xinjiang listed companies [1] - The training provided insights into compliance management and risk prevention, highlighting common issues in information disclosure and regulatory processes [1] - The event facilitated a platform for collaboration between Xinjiang enterprises and Shanghai resources, enhancing awareness of collaborative benchmarking [2] Group 2 - The association plans to continue organizing various learning exchange activities to meet enterprise development needs and promote healthy development in the Xinjiang capital market [2] - The initiative aims to deepen understanding of industrial upgrades, technological innovation, and capital operations [2] - The event strengthened the foundation for high-quality development of Xinjiang listed companies through enhanced capabilities and resource integration [2]

Group 1 - The event aimed to empower outstanding enterprises and promote the deep integration of technological and industrial innovation, organized by the G60 Joint Office [1] - This event was the 558th in the "Financial Empowerment · Building Brands" series since its inception in 2019 [1] - The event was held in a hybrid format, with over 40 representatives from G60 financial service alliance member units participating [1] Group 2 - The event featured presentations from various financial institutions, including the introduction of the G60 Technology Achievement Transformation Fund and financing guarantee policies [3] - Five companies participated in the roadshow, presenting their business models, core competencies, and financing needs [3] - There was an exchange session where professionals from banks, law firms, and accounting firms discussed market space estimates, sales forecasts, and legal issues related to the roadshow projects [3]

Core Insights - The number of projects in the innovation incubation zone has increased by over 7 times compared to the first session, showcasing significant growth in technology transfer and commercialization efforts [1][5]. Group 1: Technology and Innovation - The introduction of the Austrian monochord for clinical treatment of depression marks its first appearance at the expo, highlighting the potential of music therapy in treating various mental health conditions [1][3]. - The technology from Debecon Medical Technology Co., Ltd. focuses on gastrointestinal micro-ecological health assessment and personalized solutions, indicating a growing interest in health tech solutions in the region [3]. - The DTD platform (Digital Twin Designer) from a Japanese company is showcased for the first time in China, demonstrating its application in high-precision industrial scenarios and its potential to reduce construction time and material waste significantly [5]. Group 2: Market Opportunities - The innovation incubation zone has attracted over 500 projects this year, with an exhibition area surpassing 5,000 square meters, indicating a robust ecosystem for innovation and collaboration [5]. - Since its establishment, the zone has evolved from 3 partners to over 20 domestic and international innovation cooperation institutions, creating a diverse ecosystem that includes Fortune 500 innovation platforms and international incubators [5].

Group 1 - Hainan Lingqing Intelligent Pharmaceutical Technology Co., Ltd. has been established with a registered capital of 50 million yuan [1] - The company's business scope includes artificial intelligence industry application system integration services, AI application software development, AI public data platform, and AI basic software development [1] - The company is wholly owned by Hualan Biological Engineering Inc. (stock code: 301093) [1]

Core Insights - Zhejiang Province's Economic and Information Technology Department has released the "2025 Zhejiang Province Artificial Intelligence Application Scenarios List," which includes "AI Empowered Innovative Applications for New Drug Clinical Research" submitted by Taimei Medical Technology [1] - This selection is part of Zhejiang's efforts to implement the State Council's strategy on artificial intelligence-driven industrialization, aiming to accelerate AI innovation applications and foster deep industrial transformation [1] - The selected scenarios are required to be typical, innovative, demonstrative, and replicable [1] Company Overview - Taimei Medical Technology is a pioneer in the research and application of intelligent technology in the vertical field, having developed the "Wensi Intelligent Platform" that integrates advanced AI models and dynamic learning algorithms [1] - The platform provides reliable, usable, and perceptible AI agents for pharmaceutical research and digital marketing, including products like iDM, iCTA, iMAP, iPV, and the Wujie AI series, along with end-to-end intelligent solutions to enhance overall efficiency and commercial performance in drug development [1] Future Outlook - The company aims to continue its vision of "releasing intelligent power to make health accessible," focusing on technological research and building next-generation intelligent infrastructure for the pharmaceutical industry [2] - By driving industry transformation with smart technology and innovative thinking, the company seeks to make drug innovation more efficient, ensure safer patient medication, and improve access to quality medicines while reducing the financial burden on patients [2]

Group 1 - Shaanxi Micot Pharmaceutical Technology Co., Ltd. submitted its listing application to the Hong Kong Stock Exchange on September 29 [1] - The joint sponsors for the listing are Jianyin International and China Merchants Securities International [1]

Group 1 - The company Shaanxi Meikang Aote Pharmaceutical Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1] - The joint sponsors for the listing are Jianyin International and China Merchants Securities International [1]

Core Insights - Zhongkang Technology has launched the "Tiangong No.1 Health Industry AI Application Capability Hub," marking a new phase in the intelligent transformation of the health industry [1][4] - The "Zhuomuniao Medical Model," the core engine of the hub, has achieved the top ranking in the "Medical Language Understanding" category on the MedBench evaluation platform, showcasing its leading position in the medical AI field [1][2] Company Overview - Zhongkang Technology has been deeply integrated with the pharmaceutical industry for 18 years, combining advanced AI technology to create significant business value and strategic importance for pharmaceutical companies [1][2] AI Model Capabilities - The "Zhuomuniao Medical Model" has a scale of 70 billion parameters, enabling it to deeply analyze vast amounts of medical literature, clinical guidelines, and drug instructions, thus providing precise understanding and key information extraction [2] - The hub offers a comprehensive AI application ecosystem that empowers individuals, facilitates organizational collaboration, and fosters technological innovation [2] Individual Empowerment - The commercial intelligent agent of Tiangong No.1 provides seven professional capabilities, significantly enhancing the efficiency of pharmaceutical professionals, such as reducing the time to generate evidence reports from weeks to minutes, achieving a sevenfold increase in efficiency [2] Organizational Collaboration - The "Enterprise Growth Workbench" addresses the challenges of multi-department collaboration in pharmaceutical companies, featuring over 100 intelligent agents that enhance departmental efficiency across the entire pharmaceutical marketing chain [3] - This model breaks down departmental barriers and fosters competitive growth through a "single-point breakthrough × collaborative evolution" approach [3] Technical Foundation - The intelligent agent center serves as the technical foundation of the hub, driven by both the "Zhuomuniao Medical Model" and the "Tiangong No.1 Decision Model," integrating comprehensive market data and industry experience [3] - The multi-model collaboration capability allows for effective responses to complex medical tasks, ensuring knowledge freshness and decision relevance [3] Industry Impact - The launch of the hub is not just a technological advancement but also a foundational infrastructure for the intelligentization of the health industry, aiming to redefine work methods and decision-making processes [4] - Zhongkang Technology aspires to be a standard setter and connector in the health industry AI application ecosystem, promoting an open, innovative, and win-win environment [4][5]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 (a) 在 聯 交 所 網 站 登 載 本 公 告 並 不 引 起 本 公 司、其 聯 席 保 薦 人、整 體 協 調 人、 顧問或包銷團成員在香港或任何其他司法權區必須進行發售或配售活動 的 責 任。本 公 司 最 終 會 否 進 行 發 售 或 配 售 仍 屬 未 知 之 數； (b) 本 公 告 所 涉 及 的 上 市 申 請 並 未 獲 批 准，聯 交 所 及 證 監 會 或 會 接 納、發 回 或 拒 絕 有 關 的 公 開 發 售 及╱或 上 市 申 請； (c) 本 公 告 不 應 被 視 為 誘 使 認 購 或 購 買 任 何 證 券，亦 不 擬 構 成 該 等 勸 誘； (d) 本 公 司 或 本 公 司 的 任 何 聯 屬 公 司、其 顧 問 或 包 銷 團 成 員 概 無 於 任 何 司 法 權 區 透 過 刊 發 本 公 告 ...

Core Viewpoint - The company expects to achieve a loss attributable to shareholders of no more than 1 million HKD for the fiscal year ending June 30, 2025, representing a significant reduction of approximately 95% year-on-year [1] Financial Performance - The company's financial performance has significantly improved during the reporting period, primarily due to several factors [1] - Business improvements led to a gross profit increase of approximately 9.2 million HKD or 184% year-on-year [1] - Enhanced cost control measures for administrative and operational expenses contributed positively [1] - The company recognized loan capitalization gains of approximately 3.9 million HKD during the reporting period [1] - Financing costs decreased due to the loan capitalization, further aiding financial performance [1]